4.1.2.48: low-specificity L-threonine aldolase
This is an abbreviated version!
For detailed information about low-specificity L-threonine aldolase, go to the full flat file.
Word Map on EC 4.1.2.48
Reaction
Synonyms
GLY1, GlyA, L-TA, L-threonine aldolase, low specificity L-TA, low specificity threonine aldolase, Low-specificity L-threonine aldolase, LTA, LtaE, serine hydroxy-methyl transferase, SHMT, threonine aldolase
ECTree
4.1.2.48 low-specificity L-threonine aldolaseAdvanced search results
results (
results (Application
Application on EC 4.1.2.48 - low-specificity L-threonine aldolase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
top
APPLICATION 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
biotechnology
-
a continuous bioconversion system for L-threo-3,4-dihydroxyphenylserine production is developed that uses whole-cell biocatalyst of recombinant Escherichia coli expressing L-TA genes cloned from Streptomyces avelmitilis MA-4680. Maximum conversion rates are observed at 2 M glycine, 145 mM 3,4-dihydroxybenzaldehyde, 0.75% Triton-X, 5 g Escherichia coli cells/l, pH 6.5 and 10°C. In the optimized condition, overall productivity is 8 g/l
pharmacology
-
biotechnological potential for the syntheses of pharmaceutically relevant drug molecules because of the stereospecificity
synthesis
synthesis
production of L-threo-3,4-dihydroxyphenylserine. At the optimized conditions, a mixture of L-threo-3,4-dihydroxyphenylserine and L-erythro-3,4-dihydroxyphenylserine is synthesized by diastereoselectivity-enhanced L-threonine aldolase expressed in Escherichia coli in a continuous process for 100 h, yielding an average of 4.0 mg/ml of L-threo-3,4-dihydroxyphenylserine and 60% diastereoselectivity
synthesis
synthesis of optically active beta-hydroxy-alpha-amino acids by immobilized Escherichia coli cells expressing the enzyme. The immobilized cells can be continuously used 10 times, yielding an average conversion rate of 60.4%
synthesis
the enzyme may be exploited for bioorganic synthesis of L-3-hydroxyamino acids that are biologically active or constitute building blocks for pharmaceutical molecules
